Pliant Therapeutics, Inc. (PLRX)
Chart Events
Performance Outlook
| Previous Close | 4.9200 |
| Open | 4.7600 |
| Bid | 4.8100 x 800 |
| Ask | 4.8300 x 1100 |
| Day's Range | 4.7418 - 5.1500 |
| 52 Week Range | 3.9650 - 33.9500 |
| Volume | |
| Avg. Volume | 183,173 |
| Market Cap | 173.348M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5670 |
| Earnings Date | Mar 14, 2022 - Mar 18, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 45.67 |
- GlobeNewswire
Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company presented five scientific posters as part of the 2022 American Thoracic Society (ATS) International Conference held May 13-18, 2022, in San Francisco, California. Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics comment
- aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International ConferenceGlobeNewswire
- Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International ConferenceBusiness Wire
- GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following May investor conferences. 2022 RBC Capital Markets Global Healthcare: Dr. Coulie will participate in a fireside chat on Wednesday, May 18
- Zacks
Pliant Therapeutics, Inc. (PLRX) Reports Q1 Loss, Lags Revenue Estimates
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of -1.30% and 12.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
